<SEC-DOCUMENT>0001157523-17-001104.txt : 20170420
<SEC-HEADER>0001157523-17-001104.hdr.sgml : 20170420
<ACCEPTANCE-DATETIME>20170420170057
ACCESSION NUMBER:		0001157523-17-001104
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170420
FILED AS OF DATE:		20170420
DATE AS OF CHANGE:		20170420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		17773555

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51544368.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2017 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="text-align: center; height: 1.0 pt; color: #000000; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font>
    </p>
    <hr style="text-align: center; height: 1.0 pt; color: #000000; width: 100%">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-size: 12pt; font-family: Times New Roman">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Dated</b></font><font style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>April
      20, 2017</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="text-align: center; height: 1.0 pt; color: #000000; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="text-align: center; height: 1.0 pt; color: #000000; width: 100%">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="text-align: center; height: 1.0 pt; color: #000000; width: 100%">


    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Form 20-F &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Yes &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: Times New Roman">
      No &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font>
    </p>
    <p style="text-indent: 60.0px">

    </p>
    <p style="text-indent: 30.0px; font-size: 10pt">
      This Form 6-K is hereby filed and incorporated by reference into the
      Registrant&#8217;s Registration Statement on Form F-10 (File No. 333-206994).
    </p>
    <p style="text-indent: 60.0px">

    </p>
    <div style="width: 100%; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt">
      <tr>
        <td valign="top" style="width: 6%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated:
          </p>
        </td>
        <td valign="top" style="width: 44%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            April 20, 2017.
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 6%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="width: 44%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="width: 3%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          By:
        </td>
        <td colspan="2" valign="top" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: left; border-bottom-style: solid">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Celia Economides
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="width: 3%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="width: 5%; padding-left: 0.0px; text-align: left">
          Name:
        </td>
        <td valign="top" style="width: 42%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Celia Economides
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 6%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="width: 44%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="width: 5%; padding-left: 0.0px; text-align: left">
          Title:
        </td>
        <td valign="top" style="width: 42%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Head of IR &amp; Communications
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="width: 100%; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-family: Times New Roman; font-size: 10pt; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt">
      <tr>
        <td valign="bottom" style="width: 7%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u><b>Exhibit</b></u>
          </p>
        </td>
        <td valign="bottom" style="width: 5%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          &#160;
        </td>
        <td valign="bottom" style="width: 88%; padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: left; border-bottom-style: solid">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="width: 88%; padding-left: 0.0px; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 7%; padding-left: 0.0px; padding-right: 0.0px; text-align: left; white-space: nowrap">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="width: 88%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            News Release &#8211; <b>AURINIA RELEASES ADDITIONAL 48-WEEK DATA
            FROM THE AURA-LV STUDY DURING LATE-BREAKING SESSION AT THE
            NATIONAL KIDNEY FOUNDATION 2017 SPRING CLINICAL MEETINGS</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      Exhibit 99.1 included with this report on Form 6-K is hereby
      incorporated by reference as an exhibit to the Registrant&#8217;s Registration
      Statement on Form F-10 (File No. 333-206994), as amended or supplemented.
    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51544368ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2017 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Aurinia
      Releases Additional 48-Week Data from the AURA-LV Study During
      Late-Breaking Session at the National Kidney Foundation 2017 Spring
      Clinical Meetings</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>-Continued
      improvements in renal and extra-renal outcomes</b></font></i>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>-100%
      of patients in complete remission at week 24 stay in complete remission
      at week 48 while on low-dose voclosporin</b></font></i>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>-Renal
      function remained stable across both voclosporin groups</b></font></i>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>-Live
      webcast at 6:15pm ET</b></font></i>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--April 20, 2017--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (&#8220;Aurinia&#8221; or the
      &#8220;Company&#8221;) a clinical stage biopharmaceutical company focused on the
      global immunology market, today announced additional 48-week results
      from its global Phase IIb AURA-LV (AURA) study in lupus nephritis (LN)
      during the National Kidney Foundation 2017 Spring Clinical Meetings in
      Orlando, FL. In addition to the trial meeting its complete and partial
      remission (&#8220;CR&#8221;/&#8221;PR&#8221;) endpoints at 48 weeks, all pre-specified secondary
      endpoints that have been analyzed to date were also met at 48 weeks.
      These pre-specified endpoints include: time to CR and PR (speed of
      remission); reduction in Systemic Lupus Erythematosus Disease Activity
      Index or SLEDAI score; and reduction in urine protein creatinine ratio
      (UPCR) over the 48-week treatment period. The data were presented during
      the late-breaking session by lead author Dr. Samir Parikh, a clinical
      investigator for the study and Assistant Professor of Clinical
      Nephrology at the Ohio State University.
    </p>
    <p>
      Each arm of the study included the current standard of care of
      mycophenolate mofetil (MMF) as background therapy and a forced steroid
      taper. Both doses of voclosporin at 48 weeks demonstrated continued
      improvement over the control group across multiple dimensions. Notably,
      the voclosporin groups demonstrated statistically significantly improved
      speed and rates of CR and PR. Of the patients that achieved CR at 24
      weeks, in the low-dose voclosporin group, 100% remained in CR at 48
      weeks, which demonstrates durability of clinical response. Proteinuria
      levels and reduction in SLEDAI scores, which include non-renal measures
      of lupus activity, also continued to significantly separate over time
      versus the control group. Additional analyses are ongoing and will be
      presented at future medical and scientific meetings.
    </p>
    <p>
      No unexpected safety signals were observed and voclosporin was generally
      well-tolerated, with the nature of adverse events consistent with what
      is expected of patients suffering from highly active LN while undergoing
      immunomodulation-based therapy. In the voclosporin arms, the renal
      function as measured by eGFR was stable and not significantly different
      from the control arm during the 48-week treatment period. Mean blood
      pressure was also similar between all treatment groups.
    </p>
    <p>
      &#8220;The most exciting aspect of this data is that voclosporin is the first
      treatment candidate to successfully meet all of its clinical endpoints
      in a global, prospective LN trial,&#8221; said Dr. Samir Parikh, a clinical
      investigator for the study and Assistant Professor, Clinical Nephrology
      at the Ohio State University. &#8220;Voclosporin, when added to standard of
      care, achieved the highest complete remission rate of any global, active
      LN trial, and this was accomplished with extremely low-dose steroid
      exposure. The possibility of achieving a better clinical response while
      avoiding the significant side effects associated with prolonged exposure
      to high dose steroids has the potential to be a game-changer in the
      management of LN.&quot;
    </p>
    <div style="width: 100%; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      &#8220;We are pleased by the recognition of the medical and scientific
      communities of the AURA study results. Beyond the remission rates we&#8217;ve
      shown with voclosporin, the significant improvement in SLEDAI scores
      points towards a durable, immunological effect on a broad range of
      clinically meaningful lupus outcomes,&#8221; said Neil Solomons, MD, Aurinia&#8217;s
      Chief Medical Officer. &#8220;This data provides us with tremendous confidence
      that we can execute a successful Phase III program and make a meaningful
      impact on patients&#8217; lives.&#8221;
    </p>
    <p>
      The 24 and 48-week efficacy results are summarized below:
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 8pt">
      <tr>
        <td valign="top" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>Endpoint</b>
        </td>
        <td>
          &#160;
        </td>
        <td valign="top" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>Treatment</b>
        </td>
        <td>
          &#160;
        </td>
        <td valign="top" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>24 weeks</b>
        </td>
        <td>
          &#160;
        </td>
        <td valign="top" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>P-value*</b>
        </td>
        <td>
          &#160;
        </td>
        <td valign="top" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>48 weeks</b>
        </td>
        <td>
          &#160;
        </td>
        <td valign="top" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>P-value*</b>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="middle" rowspan="3" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>Complete Remission (CR)</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>23.7mg VCS BID</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <b>33%</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i><b>p=.045</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <b>49%</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i><b>p&lt;.001</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          39.5mg VCS BID
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          27%
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.204</i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          40%
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.026</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          Control Arm
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          19%
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          24%
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="middle" rowspan="3" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>Partial Remission (PR)</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>23.7mg VCS BID</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <b>70%</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i><b>p=.007</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>69%</b>
          </p>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i><b>p=.007</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          39.5mg VCS BID
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          66%
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.024</i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          72%
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.002</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          Control Arm
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          49%
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          48%
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="middle" rowspan="3" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>Time to CR (TTCR) [median]</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>23.7mg VCS BID</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>19.7 weeks</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i><b>p&lt;.001</b></i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>19.7 weeks</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>p&lt;.001</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          39.5mg VCS BID
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          23.4 weeks
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.001</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          23.4 weeks
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>p&lt;.001</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          Control Arm
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="middle" rowspan="3" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>Time to PR (TTPR) [median]</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>23.7mg VCS BID</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>4.1 weeks</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i><b>p=.002</b></i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>4.3 weeks</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i><b>p=.005</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          39.5mg VCS BID
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          4.4 weeks
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>P=.003</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          4.4 weeks
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.002</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          Control Arm
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          6.6 weeks
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          6.6 weeks
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="middle" rowspan="3" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>SLEDAI Reduction (non-renal lupus)</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          23.7mg VCS BID
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          -6.3
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i><b>p=.003</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          -7.9
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i><b>p&lt;.001</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          39.5mg VCS BID
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          -7.1
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.003</i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          -8.3
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>p&lt;.001</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          Control Arm
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          -4.5
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          -5.3
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="middle" rowspan="3" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>Reduction in UPCR</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>23.7mg VCS BID</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>-3.769 mg/mg</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i><b>p&lt;.001</b></i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <b>-3.998 mg/mg</b>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i><b>p&lt;.001</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          39.5mg VCS BID
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          -2.792 mg/mg
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.006</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          -2.993 mg/mg
        </td>
        <td>

        </td>
        <td valign="bottom" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i>p=.008</i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          Control Arm
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          -2.216 mg/mg
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          -2.384 mg/mg
        </td>
        <td>

        </td>
        <td valign="middle" style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-color: black; text-align: center; border-bottom-style: solid">
          <i>NA</i>
        </td>
        <td>

        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: right">
      <i>*All p-values are vs control</i>
    </p>
    <p>
      <b>Webcast Details</b><br>Aurinia will host a webcast today, April 20,
      2017 at 6:15pm Eastern Daylight Time. A live webcast of the event, with
      slides, will be available on the Investors section of the Company&#8217;s
      website at <u>http://ir.auriniapharma.com/ir-calendar</u>.
    </p>
    <p>
      <i><b>About Voclosporin</b></i><br>Voclosporin, an investigational drug,
      is a novel and potentially best-in-class calcineurin inhibitor (&#8220;CNI&#8221;)
      with clinical data in over 2,200 patients across indications.
      Voclosporin is an immunosuppressant, with a synergistic and dual
      mechanism of action that has the potential to improve near- and
      long-term outcomes in LN when added to standard of care (MMF). By
      inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell
      mediated immune responses. It is made by a modification of a single
      amino acid of the cyclosporine molecule which has shown a more
      predictable pharmacokinetic and pharmacodynamic relationship, an
      increase in potency, an altered metabolic profile, and potential for
      flat dosing. The Company anticipates that upon regulatory approval,
      patent protection for voclosporin will be extended in the United States
      and certain other major markets, including Europe and Japan, until at
      least October 2027 under the Hatch-Waxman Act and comparable laws in
      other countries.
    </p>
    <p>
      <i><b>About Lupus Nephritis (LN)</b></i><br>LN in an inflammation of the
      kidney caused by Systemic Lupus Erythematosus (&#8220;SLE&#8221;) and represents a
      serious progression of SLE. SLE is a chronic, complex and often
      disabling disorder and affects more than 500,000 people in the United
      States (mostly women). The disease is highly heterogeneous, affecting a
      wide range of organs &amp; tissue systems. It is estimated that as many as
      60% of all SLE patients have clinical LN requiring treatment. Unlike
      SLE, LN has straightforward disease outcomes where an early response
      correlates with long-term outcomes, measured by proteinuria. In patients
      with LN, renal damage results in proteinuria and/or hematuria and a
      decrease in renal function as evidenced by reduced estimated glomerular
      filtration rate (eGFR), and increased serum creatinine levels. LN is
      debilitating and costly and if poorly controlled, LN can lead to
      permanent and irreversible tissue damage within the kidney, resulting in
      end-stage renal disease (ESRD), thus making LN a serious and potentially
      life-threatening condition.
    </p>
    <div style="width: 100%; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <i><b>About Aurinia</b></i><br>Aurinia is a clinical stage
      biopharmaceutical company focused on developing and commercializing
      therapies to treat targeted patient populations that are suffering from
      serious diseases with a high unmet medical need. The company is
      currently developing voclosporin, an investigational drug, for the
      treatment of LN. The company is headquartered in Victoria, BC and
      focuses its development efforts globally. <u>www.auriniapharma.com</u>
    </p>
    <p>
      <i><b>Forward Looking Statements</b></i><br>This press release contains
      forward-looking statements, including statements related to Aurinia&#8217;s
      ability to execute a successful Phase III program and voclosporin
      potentially shifting the treatment paradigm for LN, Aurinia's analysis,
      assessment and conclusions of the results of the AURA-LV clinical study.
      It is possible that such results or conclusions may change based on
      further analyses of these data.&#160;Words such as &quot;plans,&quot; &quot;intends,&quot; &#8220;may,&#8221;
      &quot;will,&quot; &quot;believe,&quot; and similar expressions are intended to identify
      forward-looking statements. These forward-looking statements are based
      upon Aurinia&#8217;s current expectations. Forward-looking statements involve
      risks and uncertainties. Aurinia&#8217;s actual results and the timing of
      events could differ materially from those anticipated in such
      forward-looking statements as a result of these risks and uncertainties,
      which include, without limitation, the risk that Aurinia&#8217;s analyses,
      assessment and conclusions of the results of the AURA-LV clinical study
      set forth in this release may change based on further analyses of such
      data, and the risk that Aurinia&#8217;s clinical studies for voclosporin may
      not lead to regulatory approval. These and other risk factors are
      discussed under &quot;Risk Factors&quot; and elsewhere in Aurinia&#8217;s Annual
      Information Form for the year ended December 31, 2016 filed with
      Canadian securities authorities and available at <u>www.sedar.com</u>
      and on Form 40-F with the U.S. Securities Exchange Commission and
      available at <u>www.sec.gov</u>, each as updated by subsequent filings,
      including filings on Form 6-K. Aurinia expressly disclaims any
      obligation or undertaking to release publicly any updates or revisions
      to any forward-looking statements contained herein to reflect any change
      in Aurinia's expectations with regard thereto or any change in events,
      conditions or circumstances on which any such statements are based,
      except as required by law.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Aurinia Pharmaceuticals Inc.<br><b>Investor Contact:</b><br>Celia
      Economides<br>Head of IR &amp; Communications<br><u>ceconomides@auriniapharma.com</u><br>or<br><b>Media:</b><br>Christopher
      Hippolyte, 917-826-2664<br><u>Christopher.hippolyte@inventivhealth.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
